An Open-Label, Single-Center Phase II Trial of Cadonilimab (an Anti-Pd-1/ctla-4 Bispecific Antibody) in Combination with Platinum-Based Dual-Drug Neoadjuvant Chemotherapy for Locally Advanced, Resectable Head and Neck Squamous Cell Carcinoma.